Search Results for "Influenza vaccine"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Influenza vaccine. Results 1 to 10 of 24 total matches.

Influenza Vaccine for 2024-2025

   
The Medical Letter on Drugs and Therapeutics • Sep 16, 2024  (Issue 1711)
influenza vaccines improved humoral and cell-mediated immune responses and reduced influenza-related ...
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2024-2025 season are listed in Table 2.
Med Lett Drugs Ther. 2024 Sep 16;66(1711):145-50   doi:10.58347/tml.2024.1711a |  Show IntroductionHide Introduction

In Brief: FluMist Influenza Vaccine for Self-Administration

   
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024  (Issue 1714)
In Brief: FluMist Influenza Vaccine for Self-Administration ...
FluMist (AstraZeneca), the live-attenuated intranasal influenza vaccine that has been available for years for administration by a healthcare provider in nonpregnant persons 2-49 years old, has now been approved by the FDA for self- or caregiver-administration. It is expected to be available for such use during the 2025-2026 influenza season. FluMist is only available through a healthcare provider this season. It will continue to be available for administration by a healthcare provider in the future
Med Lett Drugs Ther. 2024 Oct 28;66(1714):174-5   doi:10.58347/tml.2024.1714c |  Show IntroductionHide Introduction

Antiviral Drugs for Seasonal Influenza for 2024-2025

   
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024  (Issue 1717)
on influenza activity and antiviral resistance is available from the CDC at cdc.gov/flu. TREATMENT ...
Influenza is generally a self-limited illness, but pneumonia, respiratory failure, and death can occur, especially in persons at increased risk for influenza complications (see Table 1). Updated information on influenza activity and antiviral resistance is available from the CDC at cdc.gov/flu.
Med Lett Drugs Ther. 2024 Dec 9;66(1717):193-8   doi:10.58347/tml.2024.1717a |  Show IntroductionHide Introduction

Capvaxive – A 21-Valent Pneumococcal Conjugate Vaccine

   
The Medical Letter on Drugs and Therapeutics • Oct 14, 2024  (Issue 1713)
to serotype 15C due to a similar molecular structure. influenza vaccine. Immune responses elicited when ...
The FDA has licensed Capvaxive (PCV21; Merck), a 21-valent pneumococcal conjugate vaccine, for prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia in adults. Four other pneumococcal vaccines are currently available in the US: Prevnar 20 (PCV20), Vaxneuvance (PCV15), and Prevnar 13 (PCV13) are conjugate vaccines licensed for use in persons ≥6 weeks old, and Pneumovax 23 (PPSV23) is a pneumococcal polysaccharide vaccine licensed for use in persons ≥2 years old (see Table 1).
Med Lett Drugs Ther. 2024 Oct 14;66(1713):161-3   doi:10.58347/tml.2024.1713a |  Show IntroductionHide Introduction

Baloxavir (Xofluza) for Post-Exposure Prophylaxis of Influenza

   
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021  (Issue 1615)
at increased risk of influenza complications (see Table 1) who have not received an influenza vaccine ...
The oral polymerase acidic endonuclease inhibitor baloxavir marboxil (Xofluza — Genentech) is now FDAapproved for post-exposure prophylaxis of influenza in patients ≥12 years old. Baloxavir was approved for treatment of acute uncomplicated influenza in patients ≥12 years old in 2018.1 Two neuraminidase inhibitors are FDA-approved for prophylaxis of influenza: oseltamivir (Tamiflu, and generics) in patients ≥1 year old, and zanamivir (Relenza) in patients ≥5 years old.2 Unlike oseltamivir and zanamivir, baloxavir is not FDA-approved for pre-exposure prophylaxis of...
Med Lett Drugs Ther. 2021 Jan 11;63(1615):2-3 |  Show IntroductionHide Introduction

In Brief: New Warning for the RSV Vaccines Arexvy and Abrysvo

   
The Medical Letter on Drugs and Therapeutics • Feb 17, 2025  (Issue 1722)
or bacterial infection. Administration of some COVID-19 and seasonal influenza vaccines has been associated ...
The FDA has required a new warning in the labels of the recombinant respiratory syncytial virus (RSV) vaccines Arexvy (GSK) and Abrysvo (Pfizer) about an increased risk of Guillain-Barré syndrome (GBS) within 42 days of administration of either vaccine. Both vaccines are FDA-approved to prevent lower respiratory tract disease (LRTD) caused by RSV in adults.Abrysvo is also approved for use in pregnant women at 32-36 weeks' gestation to prevent RSV-associated LRTD in their infants from birth through 6 months of age.
Med Lett Drugs Ther. 2025 Feb 17;67(1722):31-2   doi:10.58347/tml.2025.1722d |  Show IntroductionHide Introduction

Adult Immunization

   
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022  (Issue 1661)
of certain vaccines in adults residing in the US.1 Routine childhood immunization has reduced the overall ...
The Advisory Committee on Immunization Practices (ACIP) recommends use of certain vaccines in adults residing in the US. Routine childhood immunization has reduced the overall incidence of some of these vaccine-preventable diseases, but many adults remain susceptible. Recommendations for vaccination against COVID-19, seasonal influenza, and monkeypox and vaccination of travelers have been reviewed separately.
Med Lett Drugs Ther. 2022 Oct 17;64(1661):161-8 |  Show IntroductionHide Introduction

Addendum: Effectiveness of mRNA COVID-19 Vaccines (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 14, 2024  (Issue 1713)
Addendum: Effectiveness of mRNA COVID-19 Vaccines (online only) ...
A reader of our article on the 2024-2025 formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) asked us to provide more information on the data that supported their licensure.
Med Lett Drugs Ther. 2024 Oct 14;66(1713):e168   doi:10.58347/tml.2024.1713h |  Show IntroductionHide Introduction

Two Vaccines (Arexvy and Abrysvo) for Prevention of RSV Disease

   
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023  (Issue 1686)
: The CDC Advisory Committee on Immunization Practices (ACIP) recommends use of either vaccine in adults ...
Two recombinant vaccines, Arexvy (GSK) and Abrysvo (Pfizer), have been approved by the FDA for prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults ≥60 years old. They are the first RSV vaccines to be approved in the US. Abrysvo is also approved for use in pregnant women at 32-36 weeks' gestation to prevent LRTD caused by RSV in their infants from birth through 6 months of age.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):155-6   doi:10.58347/tml.2023.1686a |  Show IntroductionHide Introduction

Two New Pneumococcal Vaccines - Prevnar 20 and Vaxneuvance

   
The Medical Letter on Drugs and Therapeutics • Nov 29, 2021  (Issue 1638)
childhood immunization has resulted in a 90% reduction in vaccine-type invasive pneumococcal disease ...
The FDA has licensed two new pneumococcal conjugate vaccines (PCVs) for prevention of invasive pneumococcal disease in adults: Prevnar 20 (PCV20; Pfizer), which contains antigens from 20 serotypes of pneumococcus, and Vaxneuvance (PCV15; Merck), which contains antigens from 15 serotypes. Two other pneumococcal vaccines are available in the US: Prevnar 13 (PCV13; Pfizer), a 13-valent conjugate vaccine licensed for use in persons ≥6 weeks old, and Pneumovax 23 (PPSV23; Merck), a 23-valent pneumococcal polysaccharide vaccine licensed for use in persons ≥2 years...
Med Lett Drugs Ther. 2021 Nov 29;63(1638):188-90 |  Show IntroductionHide Introduction